

RESEARCH

Open Access

Comparative proteomics analysis of oral cancer cell lines: identification of cancer associated proteins

Saiful Anuar Karsani^{1,6*}, Nor Afiza Saihen¹, Rosnah Binti Zain², Sok-Ching Cheong^{3,5} and Mariati Abdul Rahman⁴

Abstract

Background: A limiting factor in performing proteomics analysis on cancerous cells is the difficulty in obtaining sufficient amounts of starting material. Cell lines can be used as a simplified model system for studying changes that accompany tumorigenesis. This study used two-dimensional gel electrophoresis (2DE) to compare the whole cell proteome of oral cancer cell lines vs normal cells in an attempt to identify cancer associated proteins.

Results: Three primary cell cultures of normal cells with a limited lifespan without hTERT immortalization have been successfully established. 2DE was used to compare the whole cell proteome of these cells with that of three oral cancer cell lines. Twenty four protein spots were found to have changed in abundance. MALDI TOF/TOF was then used to determine the identity of these proteins. Identified proteins were classified into seven functional categories – structural proteins, enzymes, regulatory proteins, chaperones and others. IPA core analysis predicted that 18 proteins were related to cancer with involvements in hyperplasia, metastasis, invasion, growth and tumorigenesis. The mRNA expressions of two proteins – 14-3-3 protein sigma and Stress-induced-phosphoprotein 1 – were found to correlate with the corresponding proteins' abundance.

Conclusions: The outcome of this analysis demonstrated that a comparative study of whole cell proteome of cancer versus normal cell lines can be used to identify cancer associated proteins.

Keywords: Oral cancer, Proteomics, Cell lines, Cancer associated proteins

Background

Oral cancer is a devastating disease that ranks as the fifth most common type of cancer affecting humans worldwide [1]. Incidence and mortality rates vary widely across the world. There are approximately 500,000 new oral and pharyngeal cancer cases diagnosed annually, with three quarters being registered in developing countries [2,3]. The disease is highly associated with established cultural risk factors such as tobacco chewing/smoking, alcohol consumption and betel-quid chewing [4]. In western countries, cigarette smoking and alcohol drinking are the major risk factors while betel-quid chewing and smoking are the major risk factors that

contribute to the development of oral cancer in South Asia, Southeast Asia and Taiwan [1]. Oral cancer appears as an abnormal growth within the mouth region and this include the buccal mucosa (cheek), tongue, floor of the mouth and lip. Oral squamous cell carcinoma (OSCC) represents the highest of all oral malignancy, accounting for more than 95% of total cases reported [1,3].

There is a dearth of knowledge with regards to the development and progression of oral cancer. The exact molecular mechanisms remain unknown. However, it is known to involve the activation of oncogenes, change in expression of various proteins which would eventually lead to the development of cancer. Thus, a study of proteins that change in oral cancer will provide valuable information and add to our understanding of the disease. It may also identify candidate proteins that can potentially be utilized as biomarkers for early detection. The ability of proteomics to compare differences/changes in proteome

* Correspondence: saiful72@um.edu.my

¹Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia

⁶University of Malaya Centre for Proteomics Research (UMCPR), University of Malaya, 50603 Kuala Lumpur, Malaysia

Full list of author information is available at the end of the article

profiles (including changes in post-translational modifications) which are related to tumor progression has been adapted in clinical research for the identification of biomarkers for disease such as cancer [5].

One of the main problems in performing proteomics analysis on cancerous cells is the difficulty in obtaining sufficient amounts of material to perform the analysis. The availability of cancer cell lines makes it possible to obtain an almost limitless amount of sample for proteomic analysis. Cultured cancer and normal cell lines can be used as a simplified model system for studying changes that accompany tumorigenesis. Thus, this study aims to utilize proteomics in identifying differences between proteome profiles of normal primary cultures vs oral cancer cell lines. Our results showed that such an analysis will identify cancer associated proteins.

Results and discussions

Identification of proteins with different abundance between normal primary cultures and cancer cell lines

More than 1000 individual protein spots were resolved and visualized on silver stained gels. A representative gel is shown in Figure 1. Image analysis identified 24 protein spots that exhibited significant difference in abundance ($p < 0.05$). All 24 were unambiguously identified by MALDI-TOF/TOF MS and their respective identities are shown in Table 1. The index numbers in Table 1 correspond to the numbers in Figure 1 and they indicate the location of the proteins on the 2DE gels. From this

point forward, proteins will be referred to by their abbreviated names as shown in Table 1. Table 1 includes zoomed images for all protein spots. The identified proteins were classified into seven functional categories – structural proteins, enzymes, regulatory proteins, chaperones and others. For almost all identified proteins, the experimental and theoretical pI and molecular weights were matched.

When proteins with different abundance in oral cancer were subjected to analysis using IPA, 18 were predicted to be related to cancer with involvements in hyperplasia, metastasis, invasion, growth and tumorigenesis. Table 2 shows a list of proteins known to have roles in various cancers based on IPA. Figure 2 shows a graphical representation of the predicted molecular relationships between these proteins. The predicted network involved interplay between the various proteins and suggested that changes in abundance of these proteins may influence the function of other proteins within the network. IPA also predicted that most of the proteins were of cytosolic origin.

Coordinate regulation of proteins with similar function

Two groups of proteins - detoxification enzymes and proteasome activator complex - appeared to show coordinate change in protein abundance in oral cancer.

Detoxification enzymes

Four enzymes involved in the protection of cells against oxidative stress - Lactoylglutathione lyase (LGUL), Peroxiredoxin-4 (PRDX4), Glutathione S-




Figure 1 Representative 2DE gel of whole cell proteome of cell lines. The whole cell protein of normal primary cultures and cancer cell lines were resolved by 2DE pI 4–7, 11% second dimension polyacrylamide gel. Proteins with different abundance are shown as numbered spots. The numbers correspond to Spot Number in Table 1.

Table 1 List of proteins with different abundance in cancer cell lines













Protein name	Ascension number (Swissprot)/matched 2D coordinates (World-2DPAGE portal)	MW/pI		Peptides (% cov)	Relative change vs normal	Zoomed in gel image showing representative spots		
		Theory	Experimental			Normal	Cancer	
Structural								
20	Stathmin (Phosphoprotein p19) STMN1	P16949 /SPOT 2D-001YH8	17.3/5.76	>15.0/5.7	4 (18%)	+1.6		
1	Tropomyosin alpha-3 chain (Tropomyosin-3) TPM3	P06753 / SPOT 2D-001EM1 SPOT 2D-001YBH SPOT 2D-001JNO	32.8/4.68	>30.0/4.6	6 (13%)	-1.5		
4	Myosin regulatory light chain-2 ML12A	P19105 / SPOT 2D-001JUH SPOT 2D-001JUS	19.8/4.67	>15.0/4.60	5 (17%)	-1.9		
Enzymes								
6	Lactoylglutathione lyase (Glyoxalase I). (EC 4.4.1.5) LGUL	Q04760 / n/a	20.8/5.12	>20.0/5.00	10 (22%)	+7.7		
24	Triosephosphate isomerase (EC 5.3.1.1) TPIS	P60174 / SPOT 2D-0003MP	26.7/6.45	>25.0/6.5	5 (28%)	+2.5		
18	Nucleoside diphosphate kinase A (EC 2.7.4.6) NDKA	P15531 / n/a	17.1/5.83	>15.0/5.8	8 (31%)	+1.5		
21	Ubiquitin-conjugating enzyme E2 N (EC 6.3.2.19) UBE2N	P61088 / n/a	17.1/6.13	>15.0/5.9	6 (23%)	+2.6		

Table 1 List of proteins with different abundance in cancer cell lines (Continued)











16	Gamma-glutamylcyclotransferase (EC 2.3.2.4) GGCT	O75223 / n/a	21.0/5.07	>20.0/5.0	3 (27%)	+2.5			
14	Peroxiredoxin-4 (EC 1.11.1.15) PRDX4	Q13162 / n/a	30.5/5.86	>30.0/5.8	6 (16%)	+2.2			
19	Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) SODC	P00441 / SPOT 2D-001F1V SPOT 2D-000ZXR	15.9/5.70	>15.0/5.70	5 (24%)	+1.4			
17	Glutathione S-transferase P (GST class-pi). (EC 2.5.1.18) GSTP1	P09211 / SPOT 2D-001EUM SPOT 2D-0003Q9 SPOT 2D-00085X	23.3/5.43	>25/5.6	8 (22%)	+1.4			
11	Proteasome subunit beta type 4 precursor. (EC 3.4.25.1) PSB4	P28070 / SPOT 2D-000851 SPOT 2D-000D4M	29.2/5.72	29.0/5.7	6 (15%)	+1.6			
Regulatory proteins									
3	14-3-3 protein beta/alpha 1433B	P31946 / n/a	28.0/4.70	>25.0/4.50	6 (4%)	+1.8			
12	Prohibitin PHB	P35232 / SPOT 2D-001EOL	29.8/5.57	>25.0/5.60	5 (12%)	+1.6			
13	Proteasome activator complex subunit 1 PSME1	Q06323 / SPOT 2D-001YC7	28.7/5.78	>25.0/5.70	2 (4%)	-1.7			

Table 1 List of proteins with different abundance in cancer cell lines (Continued)



















16	Proteasome activator complex subunit 2 PSME2	Q9UL46 / n/a	27.3/5.44	>30.0/5.4	4 (11%)	-2.3			
2	14-3-3 protein sigma (Stratifin) 1433S	P31947 / SPOT 2D-001EP6	27.8/4.68	>25.0/4.50	9 (24%)	-2.0			
22	Stress-induced-phosphoprotein 1 STIP1	P31948 / n/a	62.6/6.4	>55.0/6.50	11 (12%)	+2.1			
10	Interleukin-1 receptor antagonist protein precursor IL1RA	P18510 / n/a	20.0/5.83	>20.0/5.3	2 (8%)	+1.3			
5	Rho GDP-dissociation inhibitor 1 GDIR	P52565 / n/a	23.2/5.02	30.0/5.0	4 (14%)	+2.6			
9	Ran-specific GTPase-activating protein RANG	P43487 / n/a	23.3/5.19	30/5.2	5 (18%)	+1.8			
Chaperones									
15	Heat-shock protein beta-1 HSPB1	P04792 / SPOT 2D-001JQI SPOT 2D-001JQP	22.8/6.00	>20.0/5.8	11 (32%)	+3.1			
23	T-complex protein 1 subunit zeta-2 TCPW	Q92526 / n/a	57.7/6.63	>55.0/6.8	2 (2%)	-1.6			

Table 1 List of proteins with different abundance in cancer cell lines (Continued)

Others								
8	Chloride intracellular channel protein 1 (membrane associated)	O00299 /	26.9/5.09	>30.0/5.1	14 (46%)	-1.7		
	CLIC1	SPOT 2D-001YBL						


The proteins were grouped into five functional categories – structural proteins, enzymes, regulatory proteins, chaperones and others. The accession number (swiss-prot) and matched 2D coordinates, molecular weight and pI (theoretical and experimental), number of matched peptides, percentage coverage, relative change vs normal and zoomed in gel image showing representative spots are shown.

Table 2 Proteins that are known to be cancer associated based on IPA

Category	Functions annotation	p-value	Molecules	# of molecules
Cancer	Cervical tumor	1.55E-04	GSTP1, HSPB1, PHB, TPM3	4
Cancer	Breast cancer	1.82E-04	GGCT, GLO1, GSTP1, NME1, PHB, RANBP1, SOD1, TPI1	8
Cancer	Nodular hyperplasia of liver	1.25E-03	SOD1	1
Cancer	Hematological neoplasia	1.89E-03	CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1	6
Cancer	Lymphohematopoietic cancer	2.21E-03	CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1	6
Cancer	Cervical cancer	2.44E-03	GSTP1, HSPB1, TPM3	3
Cancer	Multiplicity of benign tumor	2.50E-03	GSTP1	1
Cancer	Neuroblastoma	3.33E-03	GSTP1, NME1	2
Cancer	Epidermal hyperplasia	4.24E-03	PHB, RANBP1	2
Cancer	Metastasis of melanoma	4.99E-03	IL1RN	1
Cancer	Gastric cancer	5.75E-03	GSTP1, IL1RN, PHB	3
Cancer	Digestive organ tumor	6.00E-03	GSTP1, IL1RN, NME1, PHB, SFN, SOD1, STIP1, TPI1	8
Cancer	Invasion of trophoblast	7.48E-03	NME1	1
Cancer	Urothelial bladder carcinoma	7.48E-03	GSTP1	1
Cancer	Non-small cell lung cancer	7.89E-03	GSTP1, MYL12A, STMN1	3
Cancer	Cancer	8.08E-03	CCT6B, GGCT, GLO1, GSTP1, HSPB1, IL1RN, MYL12A, NME1, PHB, PSME1, RANBP1, SFN, SOD1, STIP1, STMN1, TPI1, TPM3	17
Cancer	Liver cancer	9.35E-03	GSTP1, NME1, SOD1, TPI1	4
Cancer	Immortalization of keratinocytes	9.96E-03	SFN	1
Cancer	Invasion of extracellular matrix	1.12E-02	NME1	1
Cancer	Neoplasia of cells	1.21E-02	NME1, PHB, SFN	3
Cancer	Hematologic cancer	1.27E-02	GSTP1, NME1, PSME1, STIP1	4
Cancer	Hereditary diffuse gastric cancer	1.37E-02	IL1RN	1
Cancer	Growth of secondary tumor	1.49E-02	IL1RN	1
Cancer	Incidence of hepatocellular carcinoma	1.49E-02	SOD1	1
Cancer	Quantity of papilloma	1.61E-02	GSTP1	1
Cancer	Metastasis of cells	1.71E-02	NME1, PHB	2
Cancer	Hepatocellular carcinoma	2.21E-02	NME1, SOD1, TPI1	3
Cancer	Follicular adenoma	2.23E-02	GSTP1	1
Cancer	Waldenstrom's macroglobulinemia	2.26E-02	NME1,STIP1	2
Cancer	Acute myeloid leukemia	2.31E-02	GSTP1, PSME1	2
Cancer	Tumorigenesis of colon cancer cell lines	2.35E-02	SFN	1
Cancer	Metastasis of cancer cells	2.96E-02	PHB	1
Cancer	Infection of cervical cancer cell lines	3.05E-02	PSME2, RANBP1, STIP1	3
Cancer	Growth of melanoma	3.08E-02	IL1RN	1
Cancer	Metastasis of melanoma cell lines	3.20E-02	NME1	1

transferase P (GSTP1) and Superoxide dismutase (SODC) - were found to be in higher abundance in oral cancer. Malignant cells are in general under increased oxidative stress [6-8]. Thus, an increase of enzymes involved in protection against oxidative stress may be a mechanism to tolerate such stress.

LGUL Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Inhibitors of LGUL have been proposed as possible antitumor agents that function by inducing elevated levels of methylglyoxal in cancer cells. Methylglyoxal has been shown to inhibit the



growth of human leukaemia 60 cells in culture [9]. It has also been shown that LGUL inhibitors may also be a drug resistance-reversing agent [10]. Increase of LGUL level has been found in drug-resistant tumor cells and in invasive ovarian cancer and breast cancer [11].

PRDX4 is involved in the redox regulation of the cell. The level of peroxiredoxins (in particular PRDX3, PRDX4 and PRDX5) has been shown to be increased in cancer, suggesting the induction of PRDX as a response to increased production of reactive oxygen species in carcinomatous tissue [12].

GSTP1 conjugates reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. It plays an important role in the protection of cells from the products of oxidative stress as well as from several environmental carcinogens. The GSTP1 gene has been shown to be overexpressed in many human tumors [13].

SODC destroys radicals which are normally produced within the cells and which are toxic to biological systems. The level of SODC has been shown to increase in a number of cancers [14-16].

Proteasome activator complex

Proteasome activator complex subunit 1 (PSME1) and proteasome activator complex subunit 2 (PSME2) are implicated in immunoproteasome assembly and is required for efficient antigen processing. IPA showed that both proteins also interact and influence the function of the 26 s and 20 s proteasome. The proteasome is a multicatalytic proteinase complex that is responsible for the degradation of most intracellular proteins, including proteins that are crucial to cell cycle regulation and programmed cell death, or apoptosis. Targeting the proteasome is being investigated as a useful anticancer strategy [17]. PSME has also been proposed as a potential




Figure 3 Results of quantitative RT-PCR showing relative expressions of STMN1, 1433S, STIP1 and GSTP1. Total mRNA was extracted from normal and oral cancer cell lines. Quantitative RT-PCR was then performed as described. **A:** Relative expression of STMN1, **B:** Relative expression of 1433S, **C:** Relative expression of STIP1, **D:** Relative expression of GSTP1. Relative intensities of all genes of interest were determined by using β -actin as an internal standard. Results represent the mean \pm SD for three experiments. * $p < 0.05$.

biomarker for ovarian cancer [18]. Interestingly, our proteomics analysis showed a decrease in abundance of these proteins, whereas the proteasome activity is expected to increase in most cancers.

Proteins with higher abundance in oral cancer cell line

Structural protein

Stathmin (STMN1) is involved in the regulation of the microtubule filament system where it prevents the assembly and promotes disassembly of microtubules. It has been shown to be present at high levels in a variety of human cancers and has been proposed as a potential target in cancer therapies that disrupt the mitotic apparatus [19].

Enzymes

A number of enzymes were found to be in higher abundance in cancer cell lines. Triosephosphate isomerase (TPIS) is a glycolysis enzyme that catalyzes the reversible interconversion of triosephosphate isomers - dihydroxyacetone phosphate and D-glyceraldehyde 3-phosphate. TPIS may be associated with cancer metastasis [20].

Nucleoside diphosphate kinase A (NDKA) plays a major role in the synthesis of nucleoside triphosphates other than ATP. NDKA is involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. It has been shown to act as both a metastasis suppressor and promoter in different tumors [21].

Ubiquitin-conjugating enzyme E2 N (UBE2N) mediates the transcriptional activation of target genes. The increased abundance of UBE2N and other ubiquitin conjugating enzymes has been reported in various cancers [22-25].

Gamma-glutamylcyclotransferase (GGCT) catalyzes the formation of 5-oxoproline from gamma-glutamyl dipeptides and may play a significant role in glutathione homeostasis. It induces the release of cytochrome c from the mitochondria resulting in the induction of apoptosis. GGCT may be associated in the induction of apoptosis in leukemia U937 cells [26].

Proteasome subunit beta type 4 (PSB4) belongs to the proteasome multicatalytic proteinase complex. This complex is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.

Regulatory proteins

14-3-3 protein beta/alpha (1433B) is an adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. 1433B binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding will generally result in the modulation of the activity of the binding partner.

Prohibitin (PHB) has a role in regulating cell proliferation where it inhibits DNA synthesis. It has been shown to be involved in a number of different cancers [27-30].

Stress-induced-phosphoprotein 1 (STIP1) mediates the association of the molecular chaperones HSC70 and HSP90. STIP1 has been shown to be secreted by, and induces proliferation in glioma cells [31]. It has also been implicated in a number of other cancers [32-34].

Interleukin-1 receptor antagonist protein (IL1RA) inhibits the activity of IL-1 by binding to its receptor. The level of IL1RA has been shown to change in cancer [35-37].

Rho GDP-dissociation inhibitor 1 (GDIR) regulates the GDP/GTP exchange reaction of the Rho proteins by

inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. In cancer, GDIR has been implicated in metastasis, mediation of cancer cell motility and drug resistance [38-40].

Ran-specific GTPase-activating protein (RANG) inhibits GTP exchange on Ran and plays an essential role in nuclear transport by permitting RanGAP-mediated hydrolysis of GTP on Ran complexed to karyopherin b [41].

Chaperones

Heat-shock protein beta-1 (HSPB1) is involved in stress resistance and actin organization. Heat shock proteins (HSPs) are a large and heterogeneous group of chaperones whose synthesis can be induced by both physiological and pathological conditions, such as heat shock, oxidative stress, mitogenic signals, inflammation, infection and neoplastic transformation. Although a number of HSPs has been implicated with cancer, association of HSPB1 has not been reported.

Proteins with lower abundance in oral cancer cell line

Structural proteins

Tropomyosin alpha-3 chain (TPM3) binds to actin filaments in muscle and non-muscle cells. In association with the troponin complex, it plays a central role in the calcium dependent regulation of vertebrate striated muscle contraction.

Myosin regulatory light chain-2 (ML12A) is a myosin regulatory subunit that plays an important role in regulation of both smooth muscle and non-muscle cell contractile activity via its phosphorylation. ML12A has been implicated in cytokinesis, receptor capping, and cell locomotion. Phosphorylation of ML12A has been shown to be critical in the invasiveness of metastatic cancer cells [42].

Regulatory protein

14-3-3 protein sigma, also known as stratifin (1433S) is an adapter protein implicated in the regulation of a wide variety of both general and specialized signaling pathways. 1433S is a potential lymph node metastasis-related protein in lung squamous carcinoma [43].

Chaperones

T-complex protein 1 subunit zeta-2 (TCPW) is a molecular chaperon that assists in the folding of proteins upon ATP hydrolysis [44].

Others

Chloride intracellular channel protein 1 (CLIC1) is a protein that can insert into cellular membranes to form chloride ion channels. It has been shown that overexpression of CLIC1 promoted cell motility and invasion of low metastatic cell lines (GBC-SD18L) *in vitro*, while

RNA interference of CLIC1 decreased cell motility and invasive potency of highly metastatic cell lines (GBC-SD18H) *in vitro*, suggesting that CLIC1 may play an important role in metastasis of gallbladder carcinoma [45]. CLIC1 has also been proposed as a potential biomarker [46,47] and therapeutic target [48] for cancer.

Assessment of mRNA transcript

Quantitative real-time PCR was performed to assess the mRNA expression of four proteins - STMN1, 1433S, STIP1 and GSTP1. These proteins were selected due the marked difference in their abundance and/or possible involvement in cancer. They also represented proteins from various functional categories. The mRNA expression of all four genes was found to correlate with its corresponding protein abundance. However, only 1433S and STIP1 was found to be statistically significant (Figure 3). This suggested that these proteins may be regulated at the mRNA level.

Conclusions

We have showed that a comparative study of the oral cancer cell line proteome may identify cancer associated proteins. IPA predicted that at least 18 of these proteins were associated with cancer development and progression. At least two identified proteins (CLIC1 and PSME) have previously been proposed as potential biomarkers for cancer. Two groups of proteins (detoxification enzymes and proteasome activator complex) appeared to show coordinate change in protein abundance. Taken together, these results has demonstrated the potential of this type of study as an alternative to directly analyzing tissue samples in identifying cancer associated proteins. This study can be further extended by investigating the presence/absence of these proteins in tissue samples.

Methods

Establishment of cell cultures

This project was approved by the Medical Ethics Committee, Faculty of Dentistry, University of Malaya and endorsed by the Ministry of Health, Malaysia (DFOP1006/0041[P]). Normal tissues were derived from surgically resected tissue specimens from different impacted tooth patients. Cancerous tissues were derived from surgically resected tissue specimens from three different oral squamous cell carcinoma patients. Sample collection was performed at the Faculty of Dentistry and University Malaya Medical Centre, Kuala Lumpur Hospital and Tengku Ampuan Rahimah Hospital. All tissues were acquired after written informed consent was obtained from the patients. The oral cancer cell lines and primary cultures were derived from squamous cells and were originated from the same anatomic site (gum). Cell cultures were established as previously described [49,50].

Sample preparation and protein extraction

Cells were grown to confluence. Following trypsinization, cells were pelleted and washed 3× with PBS. The cells were then lysed by repeated freeze thawing in extraction buffer (5 M Urea, 2 M Thiourea, 2% SB3-10 and 2% CHAPS). Protein concentration was determined by Bradford assay using Bovine Serum Albumin as standard according to the manufacturer's instruction (Bio-Rad Laboratories).

Two-Dimensional Gel Electrophoresis (2DE)

For each cell line/primary culture, 2DE was performed in triplicate on protein samples extracted from three different passages of growth. Isoelectric focusing for 2DE was performed using an IPGphor system (Amersham Biosciences) according to the manufacturer's protocol. Briefly, IPG strips (24 cm Immobiline IPG Drystrip pH 4–7) were rehydrated overnight using 450 µl/strip urea rehydration stock solution (8 M Urea, 2% w/v CHAPS, 0.5% v/v Pharmalyte/IPG Buffer pH3-10, 1% trace bromophenol blue) without containing the sample. Protein extracts were solubilized in 80 µl sample lysis buffer (8 M Urea, 4% w/v CHAPS, 40 mM Tris, 65 mM DTT, 1% trace bromophenol blue) and loaded into the loading cup just before running. A total of 80 µg protein was loaded for analytical gels and 160 µg loaded for preparative gels. Isoelectric focusing was performed for 60 kVh with running conditions as follows: 500 V: 1 hour, 1000 V: 1 hour, 1000 V: 3 hours and finally a constant 8000 V at 20°C.

For the second dimension, the IPG strips were first equilibrated in 10 ml of SDS equilibration buffer (6 M Urea, 75 mM Tris-HCl pH8.8, 87% w/w glycerol, 2% SDS, 1% trace bromophenol blue) containing 1% DTT for 10 minutes, followed by a second equilibration for 10 minutes in the same equilibration buffer containing 2.5% Iodoacetamide. Equilibrated strips were then placed on 11% SDS-Polyacrylamide gel and enclosed with 0.5% agarose gel. Second dimension electrophoresis of reduced and alkylated samples was carried out using an Ettan Dalt twelve system (GE Healthcare). Electrophoresis was initially performed at 2 W for 45 minutes, followed by 110 W until the bromophenol blue dye reached the bottom edge of the gel.

Protein spots were visualized using protocols described in the PlusOne™ Silver staining kit (GE Healthcare). The complete protocol was followed for analytical gels. For preparative gels, a modified protocol was used. Glutaraldehyde was omitted from the sensitization step and formaldehyde omitted from the silver reaction step [51].

Gel image analysis

Following 2DE and silver staining, gels were scanned (Image Scanner III, GE Healthcare) and protein profiles compared using the ImageMaster Platinum 7.0 software (GE Healthcare). Protein spots were normalized using

percentage volume. Statistical analysis for the comparison of protein abundance between the groups was performed by Student's *t*-test. Only protein spots with fold difference > 1.4 and *p* < 0.05 were considered to have significantly changed in abundance.

Tryptic digestion

Protein spots were excised and in-gel digested with trypsin (Promega) for mass spectrometric identification according to published protocols [52-54].

MALDI-TOF/TOF mass spectrometry analysis and database searching

Protein identification was performed as previously described using a MALDI-TOF mass spectrometer (ABI 4800 Plus, Applied Biosystems) [55,56].

Bioinformatics

Categorization of protein function was determined based on Swiss-Prot/TrEMBL database search. Ingenuity Pathway Analysis (IPA, www.ingenuity.com) was used to determine the localization of identified proteins and their participation in molecular networks involved in carcinogenesis according to the well-established Ingenuity Knowledge Base. Details regarding proteins that were different in abundance were exported to the IPA software. Each protein identifier was then mapped to its corresponding protein object and was overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. Protein networks were then algorithmically generated based on their connectivity. A Right-tailed Fischer's exact test was used to calculate a *p*-value indicating the probability that each biological function assigned to the network is not due to chance alone.

Real-time PCR (RT-PCR)

All experiments were performed according to manufacturers' instructions. Total mRNA was extracted from cell pellets using RNAqueous®-4PCR Kit (Ambion). High Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used to reverse transcribe total mRNA into cDNA templates. RT-PCR was performed by either Taqman® Gene Expression Assay or Fast Sybr Green (Applied Biosystems).

Primers were either designed using the Primer3 software or were based on literature and PrimerBank [57,58]. The specificity of primers was examined using NCBI primer-Blast (www.ncbi.nlm.nih.gov/tools/primer-blast/). All PCR reactions were performed using the StepOnePlus Real-Time PCR instrument (Applied Biosystems). PCR conditions were defined according to the manufacturer's recommended parameters. Gene expression levels were comparatively analyzed using StepOne software v2.2. Raw data from the experiments were recalculated as a mean expression level of cancer and normal groups to generalize

the results of comparisons between the two groups. Student's unpaired t-test was then performed to determine the significance of the results.

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

SAK - principal investigator, designed and conceived the experiments, performed all MALDI-TOF/TOF analysis and prepared the manuscript. NAS - performed the experiments. RBZ - provided tissue samples from which cell lines were derived. SCC - established the cell cultures. MAR - designed and conceived the experiments and prepared the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This project was funded by University of Malaya IPPP grant PS276/2010B and eScienceFund grant SF007-2013. This research had been facilitated by access to the University of Malaya Centre for Proteomics Research (UMCPR) and Medical Biotechnology Laboratory, Faculty of Medicine, University of Malaya. We gratefully acknowledge the staff of Oral Cancer Research & Coordinating Center (OCRC), University of Malaya for assistance in normal tissues collection and Cancer Research Initiatives Foundation (CARIF) for providing cell culture facilities and other necessary equipments.

Author details

¹Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia. ²Oral Cancer Research and Co-ordinating Centre & Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia. ³Oral Cancer Research Team, 2nd Floor Outpatient Centre, Sime Darby Medical Centre, Cancer Research Initiatives Foundation (CARIF), 47500 Subang Jaya, Selangor, Malaysia. ⁴Department of Clinical Oral Biology, Faculty of Dentistry, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Malaysia. ⁵Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia. ⁶University of Malaya Centre for Proteomics Research (UMCPR), University of Malaya, 50603 Kuala Lumpur, Malaysia.

Received: 10 July 2013 Accepted: 7 January 2014

Published: 15 January 2014

References

1. Kao S-Y, Chen Y-W, Chang K-W, Liu T-Y: **Detection and screening of oral cancer and Pre-cancerous lesions.** *J Chin Med Assoc* 2009, **72**:227-233.
2. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E: **Epidemiology and prevention of oral cancer.** *Oral Oncol* 1997, **33**:302-312.
3. Lo W-Y, Tsai M-H, Tsai Y, Hua C-H, Tsai F-J, Huang S-Y, Tsai C-H, Lai C-C: **Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis.** *Clin Chim Acta* 2007, **376**:101-107.
4. Zain RB: **Cultural and dietary risk factors of oral cancer and precancer - a brief overview.** *Oral Oncol* 2001, **37**:205-210.
5. Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, Harnden P, Eardley I, Selby PJ, Banks RE: **Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma.** *Proteomics* 2006, **6**:2853-2864.
6. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P: **Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity.** *Cancer Chemother Pharmacol* 2004, **53**:209-219.
7. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J: **Advanced but not localized prostate cancer is associated with increased oxidative stress.** *J Urol* 2007, **178**:1238-1243. discussion 1243-1234.
8. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V, et al: **Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer.** *Clin Biochem* 2009, **42**:1228-1235.
9. Creighton DJ, Zheng ZB, Holewinski R, Hamilton DS, Eisman JL: **Glyoxalase I inhibitors in cancer chemotherapy.** *Biochem Soc Trans* 2003, **31**:1378-1382.
10. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T: **Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.** *Blood* 2000, **95**:3214-3218.
11. Thornalley PJ: **Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.** *Biochem Soc Trans* 2003, **31**:1372-1377.
12. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y: **Peroxioredoxins in breast carcinoma.** *Clin Cancer Res* 2003, **9**:3418-3424.
13. Primavera A, Fustinoni S, Biroccio A, Ballerini S, Urbani A, Bernardini S, Federici G, Capucci E, Manno M, Lo Bello M: **Glutathione transferases and glutathionylated hemoglobin in workers exposed to low doses of 1,3-butadiene.** *Cancer Epidemiol Biomarkers Prev* 2008, **17**:3004-3012.
14. Ansenberger-Fricano K, Mao M, Stadler K, Mason RP, Santos JH, Bonini M: **Manganese superoxide dismutase overexpression leads to cancer cell survival.** *Free Radic Biol Med* 2011, **51**:S119.
15. Radenkovic S, Milosevic Z, Konjevic Z, Karadzic K, Rovcanin B, Buta M, Gopcevic K, Jurisic V: **Lactate dehydrogenase, catalase, and superoxide dismutase in tumor tissue of breast cancer patients in respect to mammographic findings.** *Cell Biochem Biophys* 2013, **66**:287-295.
16. Skrzycki M, Majewska M, Czeczot H: **Superoxide dismutase mRNA and protein level in human colorectal cancer.** *Cen Eur J Biol* 2010, **5**:590-599.
17. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: **The proteasome as a target for cancer therapy.** *Clin Cancer Res* 2003, **9**:6316-6325.
18. Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, et al: **Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.** *J Proteome Res* 2007, **6**:4127-4134.
19. Mistry SJ, Bank A, Atweh GF: **Targeting stathmin in prostate cancer.** *Mol Cancer Ther* 2005, **4**:1821-1829.
20. Katayama M, Nakano H, Ishiuchi A, Wu W, Oshima R, Sakurai J, Nishikawa H, Yamaguchi S, Otsubo T: **Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry.** *Surg Today* 2006, **36**:1085-1093.
21. Almgren MA, Henriksson KC, Fujimoto J, Chang CL: **Nucleoside diphosphate kinase A/nm23-H1 promotes metastasis of NB69-derived human neuroblastoma.** *Mol Cancer Res* 2004, **2**:387-394.
22. Laine A, Topisirovic I, Zhai D, Reed JC, Borden KL, Ronai Z: **Regulation of p53 localization and activity by Ubc13.** *Mol Cell Biol* 2006, **26**:8901-8913.
23. Dong M, Pang X, Xu Y, Wen F, Zhang Y: **Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro.** *Int J Mol Sci* 2013, **14**:11061-11071.
24. Liang J, Nishi H, Bian ML, Higuma C, Sasaki T, Ito H, Isaka K: **The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.** *Oncol Rep* 2012, **28**:1519-1525.
25. Du H, Jie L, Xu W, Wu Y, Liu T, Li M: **A monoclonal antibody against a potential cancer biomarker, human ubiquitin-conjugating enzyme E2.** *Hybridoma (Larchmt)* 2012, **31**:196-202.
26. Masuda Y, Maeda S, Watanabe A, Sano Y, Aiuchi T, Nakajo S, Itabe H, Nakaya K: **A novel 21-kDa cytochrome c-releasing factor is generated upon treatment of human leukemia U937 cells with geranylgeraniol.** *Biochem Biophys Res Commun* 2006, **346**:454-460.
27. Najm MZ, Zaidi S, Siddiqui WA, Husain SA: **Immunohistochemical expression and mutation study of prohibitin gene in indian female breast cancer cases.** *Med Oncol* 2013, **30**:614.
28. Zhang L, Ji Q, Ni ZH, Sun J: **Prohibitin induces apoptosis in BGC823 gastric cancer cells through the mitochondrial pathway.** *Asian Pac J Cancer Prev* 2012, **13**:3803-3807.
29. Semenzato M, Cogliati S, Scorrano L: **Prohibitin(g) cancer: aurilide and killing by Opa1-dependent cristae remodeling.** *Chem Biol* 2011, **18**:8-9.
30. Wu TF, Wu H, Wang YW, Chang TY, Chan SH, Lin YP, Liu HS, Chow NH: **Prohibitin in the pathogenesis of transitional cell bladder cancer.** *Anticancer Res* 2007, **27**:895-900.
31. Erlich RB, Kahn SA, Lima FR, Muras AG, Martins RA, Linden R, Chiarini LB, Martins VR, Moura Neto V: **ST11 promotes glioma proliferation through MAPK and PI3K pathways.** *Glia* 2007, **55**:1690-1698.
32. Tsai CL, Tsai CN, Lin CY, Chen HW, Lee YS, Chao A, Wang TH, Wang HS, Lai CH: **Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells.** *Cell Rep* 2012, **2**:283-293.
33. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, Chen JK, Lin YJ, Chang PY, Wang CJ, et al: **Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation.** *Mol Cell Proteomics* 2010, **9**:1873-1884.

34. Kim S, Cho H, Nam EJ, Kim SW, Kim YT, Park YW, Kim BW, Kim JH: Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. *Genes Chromosomes Cancer* 2010, **49**:585–595.
35. Li K, Yang J, Chen ZR: Relationships among interleukin-1beta, interleukin-1 receptor antagonist gene polymorphism and susceptibility to gastric cancer. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2010, **41**:1039–1043.
36. He BS, Pan YQ, Xu YF, Zhu C, Qu LL, Wang SK: Polymorphisms in interleukin-1B (IL-1B) and interleukin 1 receptor antagonist (IL-1RN) genes associate with gastric cancer risk in the Chinese population. *Dig Dis Sci* 2011, **56**:2017–2023.
37. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ: Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. *Pharmacogenet Genomics* 2009, **19**:95–102.
38. Yamashita T, Okamura T, Nagano K, Imai S, Abe Y, Nabeshi H, Yoshikawa T, Yoshioka Y, Kamada H, Tsutsumi Y, Tsunoda S: Rho GDP-dissociation inhibitor alpha is associated with cancer metastasis in colon and prostate cancer. *Pharmazie* 2012, **67**:253–255.
39. Liu J, Zhang D, Luo W, Yu Y, Yu J, Li J, Zhang X, Zhang B, Chen J, Wu XR, et al: X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. *J Biol Chem* 2011, **286**:15630–15640.
40. Skalnikova H, Martinkova J, Hrabakova R, Halada P, Dziechciarkova M, Hajdich M, Gadher SJ, Hammar A, Enetoft D, Ekefjard A, et al: Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application. *J Proteome Res* 2011, **10**:404–415.
41. Lounsbury KM, Macara IG: Ran-binding protein 1 (RanBP1) forms a ternary complex with Ran and karyopherin beta and reduces Ran GTPase-activating protein (RanGAP) inhibition by karyopherin beta. *J Biol Chem* 1997, **272**:551–555.
42. Tohtong R, Phattarasakul K, Jiraviriyakul A, Sutthiphongchai T: Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain. *Prostate Cancer Prostatic Dis* 2003, **6**:212–216.
43. Li DJ, Deng G, Xiao ZQ, Yao HX, Li C, Peng F, Li MY, Zhang PF, Chen YH, Chen ZC: Identifying 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. *Cancer Lett* 2009, **279**:65–73.
44. Ozaki K, Kuroki T, Hayashi S, Nakamura Y: Isolation of three testis-specific genes (TSA303, TSA806, TSA903) by a differential mRNA display method. *Genomics* 1996, **36**:316–319.
45. Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng WH, Wu XS, Fei XZ, et al: Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. *Cancer Lett* 2009, **281**:71–81.
46. Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW: Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. *J Proteomics* 2013, **89**:165–178.
47. Petrova DT, Asif AR, Armstrong WW, Dimova I, Toshev S, Yarov N, Oellerich M, Toncheva D: Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. *Clin Biochem* 2008, **41**:1224–1236.
48. Suh KS, Mutoh M, Gerdes M, Yuspa SH: CLIC4, an intracellular chloride channel protein, is a novel molecular target for cancer therapy. *J Invest Dermatol Symp Proc* 2005, **10**:105–109.
49. Hamid S, Lim KP, Zain RB, Ismail SM, Lau SH, Mustafa WM, Abraham MT, Nam NA, Teo SH, Cheong SC: Establishment and characterization of Asian oral cancer cell lines as in vitro models to study a disease prevalent in Asia. *Int J Mol Med* 2007, **19**:453–460.
50. Chang HY, Hor SY, Lim KP, Zain RB, Cheong SC, Rahman MA, Karsani SA: Oral cancer secretome: identification of cancer associated proteins. *Electrophoresis* 2013, **34**:2199–2208.
51. Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ: A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. *Electrophoresis* 2000, **21**:3666–3672.
52. Jenö P, Mini T, Moes S, Hintermann E, Horst M: Internal sequences from proteins digested in polyacrylamide gels. *Anal Biochem* 1995, **224**:75–82.
53. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. *Anal Chem* 1996, **68**:850–858.
54. Wilm M, Shevchenko A, Houthaevae T, Breit S, Schweigerer L, Fotsis T, Mann M: Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. *Nature* 1996, **379**:466–469.
55. Heng EC, Karsani SA, Abdul Rahman M, Abdul Hamid NA, Hamid Z, Wan Ngah WZ: Supplementation with tocotrienol-rich fraction alters the plasma levels of Apolipoprotein A-I precursor, Apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals. *Eur J Nutr* 2013, **52**:1811–1820.
56. Thio CL, Yusof R, Abdul-Rahman PS, Karsani SA: Differential proteome analysis of chikungunya virus infection on host cells. *PLoS One* 2013, **8**:e61444.
57. Spandidos A, Wang X, Wang H, Seed B: PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. *Nucleic Acids Res* 2010, **38**:D792–D799.
58. He Y, Brown MA, Rothnagel JA, Saunders NA, Smith R: Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. *J Cell Sci* 2005, **118**:3173–3183.

doi:10.1186/1477-5956-12-3

Cite this article as: Karsani et al.: Comparative proteomics analysis of oral cancer cell lines: identification of cancer associated proteins. *Proteome Science* 2014 **12**:3.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

